

P19428.A07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jean-Philippe ROCHER, et al.

Appl. No.: 09/530,580

I.A. Filed: November 4, 1998

For: NOVEL ALKYLAMINO DERIVATIVES



Group Art Unit : 1614

Examiner : Unknown

RECEIVED
JUL 15 2002
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicant hereby brings the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the Supplementary European Search Report issued in connection with counterpart European Application No. 98 95 1687, mailed June 3, 2002. A copy of the Supplementary European Search Report is attached hereto.

WO 96/05185; and

Huseyin UCAR et al., "2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives: Novel, potent and selective σ receptor ligands", European Journal of Pharmacology, 335, pp. 267-273 (1997).

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form-1449.

P19428.A07


Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicant notes that while this Supplemental Information Disclosure Statement is being filed more than three months from the filing date, Applicant has not received an action on the merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed document is required under 37 C.F.R. 1.97(b)(3).

However, if an action on the merits has been mailed prior to the filing date of this Supplemental Information Disclosure Statement, Applicant hereby authorizes the Commissioner to charge any fees necessary to ensure consideration of the documents cited herein to Deposit Account No. 19-0089.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

Respectfully submitted,
Jean-Philippe ROCHER, et al.


Bruce H. Bernstein
Reg. No. 29,027

Regus. 33,094

July 11, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Serial No.
09/530,580

Group
1614

INFORMATION
(Use)
JUL 12 2002
PATENT & TRADEMARK OFFICE
AMINER

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
---------------------	-----------------	------	------	-------	----------	-------------------------------

RECEIVED
JUL 15 2002
TECH CENTER 1600/2900

RECEIVED
JUL 15 2002
TECH CENTER 1600/2900

[illegible]

		1	Huseyin UCAR et al., "2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives: Novel, potent and
			selective σ receptor ligands", <u>European Journal of Pharmacology</u> , 335, pp. 267-273 (1997).

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.